The thing that struck me most when I dug into this was how many women in perimenopause are still taking the same iron supplements they needed at 35 — because nobody told them the rules had changed. Heavy early-perimenopause periods can mask what's actually a trend toward retention, and by the time periods stop altogether, iron levels can be quietly elevated for years. This one really is worth a blood test conversation with your doctor.
Learn more about Rose →A typical menstrual cycle removes roughly 15–30 mg of iron per period, which is a significant ongoing drain that keeps serum ferritin and tissue iron stores within a safe range for most premenopausal women. Once periods become irregular — skipping months at a time — that iron stays in the body and ferritin levels can rise steadily. This is not a pathology in itself, but it fundamentally changes the baseline from which any iron-related risk should be assessed.
Studies tracking women across the menopausal transition show that serum ferritin begins climbing during perimenopause — often several years before the final menstrual period — as cycle frequency and flow volume both decrease. This gradual rise means iron accumulation is already underway during the years when many women are still experiencing some bleeding and may not think to question their iron status. A single ferritin test at the start of perimenopause provides a useful anchor point for tracking this shift.
The liver is the primary storage site for iron, and when input exceeds output over time, hepatic iron concentration rises in a way that promotes oxidative stress and low-grade inflammation in liver tissue. Even in the absence of hereditary hemochromatosis, elevated iron stores are associated with higher rates of non-alcoholic fatty liver disease — a condition that is itself more common after menopause due to metabolic changes driven by estrogen loss. Liver enzymes (ALT, AST) and ferritin together can offer an early signal that iron accumulation is becoming clinically relevant.
Iron participates in the Fenton reaction, a chemical process that converts hydrogen peroxide into highly reactive hydroxyl radicals capable of oxidizing LDL cholesterol — a key early step in atherosclerotic plaque formation. Several large observational studies have found that higher ferritin levels in postmenopausal women correlate with increased cardiovascular risk, independent of traditional lipid markers. This is one of the proposed mechanisms behind why women's cardiovascular risk rises sharply after menopause, alongside the well-documented loss of estrogen's protective effects.
Hereditary hemochromatosis — a common genetic condition in which the body absorbs too much iron from food — is often diagnosed later in women than men precisely because menstruation delays the clinical expression of iron overload by continuously removing excess iron. As periods become irregular in perimenopause, women who are heterozygous or homozygous carriers of HFE gene variants may see iron-related symptoms emerge or accelerate for the first time. Joint pain, fatigue, and elevated liver enzymes in a perimenopausal woman are worth evaluating alongside an iron panel, not just attributed to hormonal change.
Perimenopause often starts with heavier, more erratic periods rather than lighter ones, which legitimately raises short-term iron requirements and may lead a doctor to recommend supplementation. The problem arises when supplementation continues unchanged as periods become infrequent and lighter — a common scenario because follow-up iron testing is often not prioritised once the acute heavy-bleeding phase passes. Continuing high-dose iron supplementation into the later stages of perimenopause, when losses have diminished, can accelerate the accumulation that was already beginning to occur naturally.
Iron excess has a well-documented toxic effect on pancreatic beta cells — the cells responsible for producing insulin — and also interferes with insulin receptor signalling in liver and muscle tissue. Meta-analyses in general adult populations show a consistent association between high ferritin levels and increased risk of type 2 diabetes, a risk that compounds with the insulin resistance that commonly develops during the menopausal transition due to declining estrogen. Women entering perimenopause with already-elevated ferritin are effectively adding one metabolic stressor on top of another.
Ferritin is an acute-phase protein, meaning it rises during inflammation regardless of actual iron stores — a complication that is particularly relevant in perimenopause, when low-grade systemic inflammation is common due to hormonal fluctuation. This means a single elevated ferritin result does not automatically confirm iron overload, and conversely, a normal ferritin in a highly inflamed state can mask true accumulation. A complete iron panel — including transferrin saturation, serum iron, and ideally a C-reactive protein to flag inflammation — gives a far more accurate picture than ferritin alone.
For women without hereditary hemochromatosis who are simply navigating the natural rise in iron stores during perimenopause, dietary strategies can help moderate absorption without any pharmaceutical intervention. Pairing iron-rich meals with polyphenol-rich foods — such as coffee, tea, or legumes — reduces non-haem iron absorption, while reducing high-dose vitamin C supplementation taken alongside red meat can blunt the absorption-enhancing effect of ascorbic acid. These are not dramatic interventions, but they represent genuinely evidence-supported levers that are worth knowing about during a period of life when iron's exit route is narrowing.
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.